- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Numéro de téléphone: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
Sauvegarde des contacts de l'étude
- Nom: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Numéro de téléphone: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
Lieux d'étude
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Inde, 522503
- Recrutement
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Contact:
- Dr S Sathiyanarayanan, MBBS., MD
- Numéro de téléphone: 08645 280021
- E-mail: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, Inde, 781101
- Actif, ne recrute pas
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, Inde, 360001
- Pas encore de recrutement
- Govt. PDU Medical College
-
Contact:
- Dr Bhoomika Patel, MBBS., MD
- Numéro de téléphone: 0281 245 8337
- E-mail: doctorbhoomika@gmail.com
-
Surat, Gujarat, Inde, 395001
- Actif, ne recrute pas
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, Inde, 400008
- Recrutement
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Contact:
- Dr Priti Meshram, MBBS., MD., DNB
- Numéro de téléphone: 022 2373 5555
- E-mail: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, Inde
- Pas encore de recrutement
- All India Institute Of Medical Sciences, Nagpur
-
Contact:
- Dr Yogesh Bahurupi, MBBS., MD
- Numéro de téléphone: 0712 2352078
- E-mail: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, Inde, 793018
- Recrutement
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Contact:
- Dr Monaliza Lyngdoh, MBBS., MD
- Numéro de téléphone: 0364 2538013
- E-mail: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Inde, 110030
- Pas encore de recrutement
- National Institute of TB and Respiratory Diseases
-
Contact:
- Dr Jitendra Kumar Saini, MBBS., MD
- Numéro de téléphone: 011 2651 3325
- E-mail: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, Inde, 751019
- Actif, ne recrute pas
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, Inde, 751001
- Actif, ne recrute pas
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Inde, 600031
- Recrutement
- ICMR - National Institute for Research in Tuberculosis
-
Contact:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Numéro de téléphone: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
-
Contact:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Numéro de téléphone: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
-
Chercheur principal:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Chercheur principal:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Sous-enquêteur:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, Inde, 500038
- Recrutement
- Govt. General and Chest Hospital, Osmania Medical College
-
Contact:
- Dr V Karthik, MBBS., MD
- Numéro de téléphone: 04083814421
- E-mail: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, Inde, 282002
- Recrutement
- Sarojini Naidu Medical College
-
Contact:
- Dr Gajendra Vikram Singh, MBBS., MD
- Numéro de téléphone: 0562 2260353
- E-mail: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, Inde, 211002
- Recrutement
- Moti Lal Nehru Medical College
-
Contact:
- Dr Amitabh Das Shukla, MBBS., MD
- Numéro de téléphone: 0532 261 3592
- E-mail: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, Inde, 226003
- Recrutement
- King George Medical University
-
Contact:
- Dr Rajiv Garg, MBBS., MD
- Numéro de téléphone: 0522 2255167
- E-mail: rajivkgmc@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Expérimental: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Expérimental: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Comparateur actif: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Délai: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Délai: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Délai: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Délai: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Délai: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Délai: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Chercheur principal: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publications et liens utiles
Publications générales
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Infections des voies respiratoires
- Infections
- Maladies des voies respiratoires
- Maladies pulmonaires
- Infections bactériennes à Gram positif
- Infections bactériennes
- Infections bactériennes et mycoses
- Infections à Actinomycétales
- Infections à mycobactéries
- Tuberculose
- Tuberculose pulmonaire
- Qualité des soins de santé, accès et évaluation
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Thérapeutique
- Mécanismes d'évaluation des soins de santé
- Qualité des soins de santé
- Composés polycycliques
- Composés hétérocycliques, 4 anneaux ou plus
- Rifamycines
- Lactams, macrocyclique
- Composés macrocycliques
- Fluoroquinolones
- 4-quinolones
- Quinolones
- Quinolines
- Ofloxacine
- Caractéristiques de l'étude épidémiologique
- Rifampicine
- Lévofloxacine
- Protocoles cliniques
Autres numéros d'identification d'étude
- 2025 011
- CTRI/2026/02/102698 (Identificateur de registre: CLINICAL TRIALS REGISTRY - INDIA)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .